Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010841 · ClinicalTrials.gov registry record · NA
Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome
A NA study, sponsored by MetaProteomics.
- Completed
- Registry status
- NA
- Development phase
- 89
- Enrollment target
NCT01010841: Completed NA study, sponsored by MetaProteomics.
NCT01010841 is a NA study that has completed, run by MetaProteomics. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01010841, a NA study, has completed, sponsored by MetaProteomics.
- COMPLETED
- Registry status
- NA
- Development phase
- 89 participants
- Enrollment target
Study Summary
The objective of this study was to investigate from 3 sites (University of Connecticut, University of Florida, and University of California, Irvine) whether enhancement of a modified Mediterranean-style, low glycemic load diet (MED) with specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED) could improve cardiometabolic risk factors in women with metabolic syndrome.
Interventions
- DIETARY_SUPPLEMENT UltraMealPlus 360 (Medical food)
- OTHER Low-glycemic-load diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-04 |
| Phase | NA |
What the finished NCT01010841 record still lists
NCT01010841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which UltraMealPlus 360 (Medical food) is the first listed.
NCT01010841 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01010841 about?
NCT01010841 is a clinical study titled "Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome". The objective of this study was to investigate from 3 sites (University of Connecticut, University of Florida, and University of California, Irvine) whether enhancement of a modified Mediterranean-style, low glycemic load diet (MED) with specific phytochemicals (soy protein, phytosterols, rho iso-al...
What is the current status of trial NCT01010841?
This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2008-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01010841?
The interventions under investigation include: UltraMealPlus 360 (Medical food) (DIETARY_SUPPLEMENT), Low-glycemic-load diet (OTHER).
Who is sponsoring clinical trial NCT01010841?
This trial is sponsored by MetaProteomics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01010841's enrollment target sits among peer trials
89 972nd of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia